AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

12,446.00p
   
  • Change Today:
    -252.00p
  • 52 Week High: 15,316.00p
  • 52 Week Low: 11,460.00p
  • Currency: UK Pounds
  • Shares Issued: 1,551.05m
  • Volume: 2,876,560
  • Market Cap: £193,044m
  • RiskGrade: 123
  • Beta: 0.00

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart (16-10-2026)

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

AstraZeneca Financials

Latest F'cast
Div Yield 1.9% 0.0%
Div Cover 2.1 3.0
Op Mrgn 23.4% 31.6%
ROCE 59.5%  
Latest F'cast
P/E 26.0 20.4
PEG 0.6 n/a
Pr/Revenue 4.5 3.8
Pr/Book 5.5  
Latest F'cast
Revenue 8.6% -19.3%
PBT 42.7% 20.8%
EPS 45.4% 54.1%
DPS 3.2% -40.9%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-21 37,417.00 (265.00) 8.00¢ 1,446.0 n/a -97% 287.00¢ 2.5%
31-Dec-22 44,351.00 2,501.00 212.00¢ 70.5 0.0 +2,550% 290.00¢ 1.9%
31-Dec-23 45,811.00 6,899.00 726.00¢ 19.5 0.1 +242% 290.00¢ 2.1%
31-Dec-24 54,073.00 8,691.00 454.00¢ 30.7 n/a -38% 310.00¢ 2.2%
31-Dec-25 58,739.00 12,402.00 660.00¢ 27.9 0.6 +45% 320.00¢ 1.7%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-26 63,200.47 19,969.36 768.24p 16.5 0.3 +54% 251.94p 0.0%
31-Dec-27 67,039.74 22,072.30 853.77p 14.9 1.3 +11% 266.98p 0.0%

Copyright © 2026 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

AstraZeneca completes equity investment in Summit 05-Oct-2026 12:00 RNS
AZ & DS collaboration with Summit for Datroway 02-Oct-2026 07:30 RNS
Admission of Further Securities to Trading 01-Oct-2026 15:05 RNS

AstraZeneca ShareCast News

AstraZeneca enters into strategic drug discovery... 15-Oct-2026 ShareCast
AstraZeneca to invest $2bn in Summit Therapeutics 29-Sep-2026 ShareCast
Astrazeneca's Trixeo Aerosphere secures EU appro... 23-Sep-2026 ShareCast

AstraZeneca Top Newspaper Links

AstraZeneca takes $2bn stake in US cancer specia... 29-Sep-2026 Times
Is now the right time to buy shares in AstraZene... 04-Aug-2026 Times
AstraZeneca shares fall on Bristol Myers Squibb ... 03-Aug-2026 Times

Latest AstraZeneca Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 12,446.00p
Change Today -252.00p
% Change -1.98 %
52 Week High 15,316.00p
52 Week Low 11,460.00p
Volume 2,876,560
Shares Issued 1,551.05m
Market Cap £193,044m
Beta 0.00
RiskGrade 123

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.35% below the market average93.35% below the market average93.35% below the market average93.35% below the market average93.35% below the market average
90% below the sector average90% below the sector average90% below the sector average90% below the sector average90% below the sector average
Price Trend
11.83% above the market average11.83% above the market average11.83% above the market average11.83% above the market average11.83% above the market average
48.84% above the sector average48.84% above the sector average48.84% above the sector average48.84% above the sector average48.84% above the sector average
Income
66.12% below the market average66.12% below the market average66.12% below the market average66.12% below the market average66.12% below the market average
60% below the sector average60% below the sector average60% below the sector average60% below the sector average60% below the sector average
Growth
86.72% above the market average86.72% above the market average86.72% above the market average86.72% above the market average86.72% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average

What The Brokers Say

Strong Buy 10
Buy 7
Neutral 6
Sell 0
Strong Sell 0
Total 23
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  1st Interim 2nd Interim
Ex-Div 06-Aug-26 19-Feb-26
Paid 08-Sep-26 23-Mar-26
Amount 106.00¢ 217.00¢

Trades for 16-Oct-2026

Time Volume / Share Price
10:14 300,000 @ 12,506.00p
16:59 873 @ 12,473.39p
16:59 2,264 @ 12,480.01p
16:38 1,551 @ 12,446.00p
16:38 64 @ 12,446.00p

AstraZeneca Key Personnel

Chair Michel Demare

Top of Page